Receptos (RCPT) Posts Mixed Q3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Receptos (RCPT) PT Raised to $141 at Nomura as UC Could Be Bigger Than MS
November 5, 2014 10:11 AM ESTNomura Securities analyst M. Ian Somaiya reiterated a Buy rating and boosted his price target on Receptos, Inc (NASDAQ: RCPT) to $141.00 (from $136.00) following Q3 results saying ulcerative colitis (UC) could be bigger than multiple sclerosis (MS).
Somaiya commented, "We are increasing... More
